Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Al-Ola Abdallah provided an overview of the DREAMM-7 trial, a multicenter phase 3 study in which belantamab mafodotin plus bortezomib and dexamethasone demonstrated a progression-free survival of approximately 3 years compared with 13 months for the daratumumab plus bortezomib and dexamethasone comparator arm, along with a 42% reduction in the risk of death and higher rates of minimal residual disease (MRD) negativity.

The panelists discussed how BCMA-targeted therapies have rapidly evolved from last-resort options for heavily pretreated patients to agents now considered earlier in the treatment continuum, driven by their remarkable response rates, depth of response, and improving survival outcomes.

In 'Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management,' our panel of experts delve into the following critical question:

In this episode, 'When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs,' the oncology pharmacists explore the following question:

In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions: What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma? What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options? How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies? What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies? What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question: What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:

In 'When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma,' our panel of experts delve into the following critical question:

In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question: 1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?

Welcome back to another Pharmacy Times Practice Pearls series. In this episode, titled "Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge," Zahra Mahmoudjafari led the conversation about the following question: Transitions of care are the single most consistent operational challenge, outranking efficacy and safety concerns. Why are they difficult, and where are the pain points?

Pharmacy streamlines bispecific programs with tailored operations, scheduling, order sets, and reimbursement checkpoints.

Leaders unpack governance, SOP scalability, and payer hurdles in cell and gene therapy program development, helping the cell and gene therapies community build sustainable programs.

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, from the University of Kansas Cancer Center talks about bispecifics and the value of building a network to communicate operationalizing these therapies across clinics.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

Explore the latest advancements in myelofibrosis therapies, including innovative treatments and the evolving role of pharmacists in patient care.

New findings on myelofibrosis treatments reveal the impact of anemia on survival and the benefits of momelotinib for transfusion independence.

Pharmacists play a crucial role in managing myelofibrosis treatment, ensuring patient education, medication access, and monitoring for adverse effects.

Experts discuss the need for improved clinical trials in myelofibrosis, focusing on disease modification, patient outcomes, and potential new therapies.

Explore how real-world evidence shapes myelofibrosis treatment, focusing on biomarker utilization and safety profiles of JAK inhibitors.

Explore the latest advancements in myelofibrosis treatments, including Fedratinib, Pacritinib, and Momelotinib, and their clinical impacts.

The epcoritamab, rituximab, and lenalidomide regimen provides a chemo-free, outpatient option for relapsed or refractory follicular lymphoma (FL), offering high response rates, improved quality of life, and expanding pharmacists’ roles in patient management.

Zahra Mahmoudjafari explains how the epcoritamab, rituximab, and lenalidomide regimen delivers durable responses in relapsed or refractory follicular lymphoma while expanding the pharmacist’s role in dosing coordination and toxicity management.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, explains how the epcoritamab, rituximab, and lenalidomide regimen delivers durable responses in relapsed or refractory follicular lymphoma while expanding the pharmacist’s role in dosing coordination and toxicity management.

Explore the latest advancements in JAK inhibitors for myelofibrosis, highlighting their unique mechanisms and clinical implications for patient care.

Explore the evolution of myelofibrosis treatments, from traditional therapies to groundbreaking JAK inhibitors, and the ongoing need for innovative solutions.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, highlights the EPCORE FL-1 trial, which showed that adding epcoritamab to rituximab and lenalidomide improved response rates and reduced progression risk in patients with relapsed or refractory follicular lymphoma.

Explore the long-term effects of myelofibrosis and the importance of early diagnosis and treatment for better patient outcomes.